Skip to main content
MNKDMannKind CorporationSell6.2·$3.85
SellModerate Confidence
Investment thesis

MannKind is growing revenue about 24% YoY and trades 80.9% below the $7.06 analyst target, but it is cash-burning with a -230.6% operating margin, three recent EPS misses and sole-supplier concentration risk.

Thesis pillars

  • Strong Revenue Growth→Stable
  • Deep Discount To Analyst Target↑Improving
  • Cash Burn And Weak Quality→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 8, 2026, based on the 10-K filed Feb 26, 2026

Full reasoning →

Open full analysis

MannKind Corporation (MNKD) Stock Analysis

Range Bound setup · Inst Constrain edge

SellVALUE-TRAP 3/5GrowthModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.

MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company... Read more

$3.85+88.3% A.UpsideScore 6.2/10#23 of 240 Biotechnology
QualityF-score6 / 9FCF yield-0.49%
Stop $3.58Analyst target $7.25(−13% haircut)A.R:R 5.9:1
Analyst consensus$8.33+116.5%9 analysts with price targets
$7.25Analyst target
$3.85price
$8.33mean
$13

Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 6.2/10, moderate confidence.

Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 95d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 19, 2026

Recent Developments — MannKind Corporation

Latest item Nov 19, 2026 · Generated 2026-11-22T11:37:10Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Feb 25, 202795d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza)
Quality below floor (3.8 < 4.0)
Value-trap signals (3/5): Margin compression (op margin -900.1%), Material insider selling (3 sells, 0.20% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)24.4
Mkt Cap$1.2B
EV/EBITDA-885.6
Profit Mgn-18.1%
ROE—
Rev Growth24.0%
Beta1.09
DividendNone
Analysts with ratings15

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C0.51bullish
IV130%elevated

Concentration Risks(10-K Item 1A)

  • HIGHSupplierAmphastar (sole insulin supplier for Afrezza)
    10-K Item 1: 'Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar France Pharmaceuticals S.A.S. (“Amphastar”).'
  • MEDIUMcounterpartyUnited Therapeutics (Tyvaso DPI commercialization)
    10-K Item 1A: 'A significant portion of our revenue is derived from royalties and collaboration and services revenue associated with United Therapeutics’ commercialization of Tyvaso DPI.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
News Activity
6.0
Earnings concerns: 0B/3M

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Piotroski F
6.7
Moat
7.0
Current Ratio
7.6
Gross Margin
10.0
Cash-burning: FCF -1% of revenueRule of 40: 23 (fail)
GatesDeath cross (50MA < 200MA)Momentum 4.6<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.6>=4.5A.R:R 5.9 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 95d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Speculative
RSI
57 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $3.15Resistance $4.29

Price Targets

$4
$7
A.Upside+88.3%
A.R:R5.9:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.8 < 4.0)
! Value-trap signals (3/5): Margin compression (op margin -900.1%), Material insider selling (3 sells, 0.20% of cap), Negative free cash flow
! Death cross — 50-day MA below 200-day MA

Earnings

M
M
M
M
0/4 beats
Next Earnings2027-02-25 (95d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MNKD stock a buy right now?

Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $3.58. Score 6.2/10, moderate confidence.

What is the MNKD stock price target?

Analyst target: $7.25 (+88.3% upside). Prior stop was $3.58. Stop-loss: $3.58.

What are the risks of investing in MNKD?

Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza); Quality below floor (3.8 < 4.0); Value-trap signals (3/5): Margin compression (op margin -900.1%), Material insider selling (3 sells, 0.20% of cap), Negative free cash flow.

Is MNKD overvalued or undervalued?

MannKind Corporation trades at a P/E of N/A (forward 24.4). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about MNKD?

15 analysts rate MNKD, with a consensus score of 4.1/5. 9 analysts publish price targets averaging $8.

What does MannKind Corporation do?MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on...

MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company depends on a single qualified insulin supplier, Amphastar, under a €120.1 million purchase commitment, and on United Therapeutics' continued commercial prioritization of Tyvaso DPI.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · HALO (Halozyme Therapeutics, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I)
Home › Stocks › MNKD

Latest news

Latest News

TradingKey116d ago
Tradingkey.com116d ago
Marketscreener.com109d agoEarnings
DirectorsTalk Interviews110d ago
Dars.gov.et115d ago
GuruFocus115d agoAnalyst
TradingKey115d ago
Ad-hoc-news.de24d agoEarnings
Yahoo Finance21d ago
Yahoo Finance22d ago
Simplywall.st113d ago
Stocktwits111d ago
Simply Wall St20d agoProduct
Seeking Alpha114d ago
Stocktwits114d ago
The Globe and Mail114d ago
TradingKey114d ago
Seeking Alpha114d agoProduct
Finviz23d ago
Fiscal.ai3d ago
Loading more...